Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various
skin disorder including
acne,
psoriasis,
ichthyosis,
photoaging, photodamaged
skin, and,
skin cancer. Exemplary
vitamin D analogs as active pharmaceutical ingredients include 2-
methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-
methylene-1α,25-dihydroxyvitamin D3, 2-
methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-
vitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20S)-1α-hydroxyvitamin D3, 2-methylene-18,19-dinor-(20S)-1α,25-dihydroxyvitamin D3, a stereoisomer thereof, a
prodrug thereof in oral compositions, a salt thereof, and / or a solute thereof. Compounds that activate
retinoic acid receptors, such as retinoyls and retinoyl esters, include 13-cis-
retinoic acid, all-trans-
retinoic acid, (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexeneyl)nona-2,4,6,8-tetraenoic acid, 9-(4-methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid, 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-napthoic acid, 4-[1-(3,5,5,8,8-pentamethyl-
tetralin-2-yl)ethenyl]
benzoic acid, retinobenzoic acid, ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]
pyridine-3-
carboxylate, retinoyl t-
butyrate, retinoyl
pinacol, retinoyl
cholesterol, an isomer thereof, a
prodrug thereof for oral compositions, an ester thereof, a salt thereof, and / or, a solute thereof. Combinations of such active ingredients demonstrate synergistic
efficacy.